Literature DB >> 19376726

A novel boronated-porphyrin as a radio-sensitizing agent for boron neutron capture therapy of tumours: in vitro and in vivo studies.

G Jori1, M Soncin, E Friso, M G H Vicente, E Hao, G Miotto, P Colautti, D Moro, J Esposito, G Rosi, E Nava, G Sotti, C Fabris.   

Abstract

A water-soluble [meso-tetra(4-nido-carboranylphenyl)porphyrin] (H(2)TCP) bearing 36 boron atoms was studied for its accumulation and its radio/photo-sensitization efficiency towards murine melanotic melanoma cells. The amount of H(2)TCP in the cells increased with the porphyrin dose in the incubation medium up to 100 microM with no significant dark toxicity. Fluorescence microscopy observations showed that the porphyrin was largely localized intracellularly. Based on these "in vitro" results our investigations were pursued using the B16F1 melanotic melanoma subcutaneously transplanted in C57BL6 mice as "in vivo" model. Phormacokinetic studies were performed by injection of H(2)TCP intratumorally (1 mg/kg) and intravenously (10 mg/kg). At 0.5h after i.t. administration or at 24 h after i.v. injection, the amounts of (10)B in the tumour were about 60 ppm and about 6 ppm, respectively. The distribution of H(2)TCP in the tumour after intravenous or intratumoural injection was also assessed by fluorescence microscopy analyses. Under these conditions, preliminary BNCT studies were carried out using a new thermal column called HYTOR (HYbrid Thermal spectrum sHifter TapirO Reactor) inserted in the fast nuclear reactor Tapiro at Enea Casaccia, Italy. The mice were exposed to HYTHOR radiation field for 20 min at a reactor power of 5 kW. In spite of different amounts of (10)B in the tumour at the irradiation time, a similar significant delay in tumour growth (5-6 days) was induced by neutron irradiation in intratoumorally and intravenously injected mice. The response of the melanotic melanoma to H(2)TCP-BNCT was compared with that obtained by irradiation after intraperitoneal injection of boron-phenylalanine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19376726     DOI: 10.1016/j.apradiso.2009.03.071

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  5 in total

Review 1.  Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy.

Authors:  Micah John Luderer; Pilar de la Puente; Abdel Kareem Azab
Journal:  Pharm Res       Date:  2015-06-02       Impact factor: 4.200

2.  Convection enhanced delivery of carboranylporphyrins for neutron capture therapy of brain tumors.

Authors:  Shinji Kawabata; Weilian Yang; Rolf F Barth; Gong Wu; Tianyao Huo; Peter J Binns; Kent J Riley; Owendi Ongayi; Vijay Gottumukkala; M Graça H Vicente
Journal:  J Neurooncol       Date:  2010-09-17       Impact factor: 4.130

Review 3.  N3-substituted thymidine bioconjugates for cancer therapy and imaging.

Authors:  Ahmed Khalil; Keisuke Ishita; Tehane Ali; Werner Tjarks
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

4.  Study of efficiency of the modular nanotransporter for targeted delivery of photosensitizers to melanoma cell nuclei in vivo.

Authors:  T A Slastnikova; A A Rosenkranz; T N Lupanova; P V Gulak; N V Gnuchev; A S Sobolev
Journal:  Dokl Biochem Biophys       Date:  2012-11-07       Impact factor: 0.788

5.  Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery.

Authors:  Tatiana A Slastnikova; Andrey A Rosenkranz; Pavel V Gulak; Raymond M Schiffelers; Tatiana N Lupanova; Yuri V Khramtsov; Michael R Zalutsky; Alexander S Sobolev
Journal:  Int J Nanomedicine       Date:  2012-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.